Corporate Growth is a fundamental driver of competitiveness and valuations for MedTech and Life Science companies. Corporations who enjoy high growth rates also experience better competitive positions, expanded market opportunities, and greater financial flexibility. In parallel, evidence shows that a focus on mid-term innovation, building products that open or expand markets in the 2-5-year time frame, is a successful strategy for sustaining corporate growth.

In this webinar, Triple Ring and LSX have convened a panel of experts to discuss corporate growth strategies that leverage innovation and build-to-buy deals to accelerate growth in the MedTech and Life Science industries. Co-development frameworks enable corporations to de-risk midterm innovation off the balance sheet, validate technologies, and maintain acquisition optionality. Such structured deals enable faster time to market, alignment across technology, regulatory, and product domains, and improved commercialization success.

This session offers actionable insights for corporate strategists, investors, technology and product developers, and entrepreneurs.

The expert panel will address:

• Build to Buy and other shared-risk engagement models
• Combining internal R&D excellence with external innovation to drive growth
• Shared-risk structures applied to transformative technology domains like neurotechnology, robotics, digital health and precision health
• Leveraging mid-term innovation projects for long-term growth
• Creative financing models that include Venture Capital and Private Equity

Sponsored by:

Speakers:

Ryan McGuinness (Moderator)
Chief Growth Officer
Triple Ring

Joe Heanue
Co-Founder and CEO
Triple Ring

John Pennet
Partner-in-Charge of the Technology and Life Sciences practice
Eisner Advisory Group LLC

Francois Valencony
Chief Investment & Business Officer
General Inception